Skip to content

Observation on the Clinical Efficacy of Dujiu in Treating Chronic Fatigue Syndrome of Spleen and Kidney Yang Deficiency Type

Observation on the Clinical Efficacy of Dujiu in Treating Chronic Fatigue Syndrome of Spleen and Kidney Yang Deficiency Type

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000448
Enrollment
Unknown
Registered
2026-03-03
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic fatigue syndrome

Interventions

Experimental group :Du moxibustion treatment
control group:TDP lamp irradiation treatment

Sponsors

Huaibei People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for CFS in Western medicine; And it meets the diagnostic criteria for the syndrome of spleen and kidney Yang deficiency in traditional Chinese medicine. (2) 18 years old to 70 years old, gender not limited; (3) No serious organic diseases, such as heart disease, lung disease, liver disease or kidney disease, etc. (4) During this treatment process, the patient did not take any other therapeutic drugs for this condition. (5) The patient was informed and agreed to participate in this study and signed the informed consent form. Only patients who meet all the above five conditions simultaneously can be included in this study

Exclusion criteria

Exclusion criteria: (1) The patient has diseases that can explain the cause of chronic fatigue, as well as other organic diseases, resulting in symptoms similar to those of CFS. (2) The patient is undergoing other therapies or participating in other studies; (3) Pregnant or lactating women; (4) The patient has allergic rashes, infections and other skin diseases on the back. Those with open wounds and hypertrophic scars. Patients who meet any of the above conditions should be excluded.

Design outcomes

Primary

MeasureTime frame
Efficacy evaluation indicators;Molecular biological indicators;Efficacy assessment;

Secondary

MeasureTime frame
Demographic indicators and baseline indicators;

Countries

China

Contacts

Public ContactLei liu

Huaibei People's Hospital

liuleizj@ahtcm.edu.cn13739220424

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026